| Date Filed | Type | Description |
| 05/23/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Sold 4,300 shares
@ $216.9086, valued at
$932.7k
Exercised 4,300 options to buy
@ $182.51, valued at
$784.8k
|
|
| 05/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/03/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 6,763 shares
@ $0
Paid exercise price by delivering 2,886 shares
@ $224.7, valued at
$648.5k
|
|
| 02/23/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Sold 8,000 shares
@ $250.5844, valued at
$2M
Exercised 3,000 options to buy
@ $182.51, valued at
$547.5k
|
|
| 02/14/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 142 shares
@ $248.13, valued at
$35.2k
Exercised 483 restricted stock units
@ $0 |
|
| 02/09/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 1,590 restricted stock units
@ $0
Granted 5,000 options to buy
@ $247.24, valued at
$1.2M
|
|
| 02/07/2023 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 164 shares
@ $244.5, valued at
$40.1k
Exercised 560 restricted stock units
@ $0 |
|
| 02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 892 shares
@ $222.56, valued at
$198.5k
Exercised 2,007 restricted stock units
@ $0 |
|
| 03/29/2022 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 3,707 shares
@ $0
Paid exercise price by delivering 1,648 shares
@ $276.42, valued at
$455.5k
|
|
| 02/15/2022 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 108 shares
@ $272.68, valued at
$29.4k
Granted 1,450 restricted stock units
@ $0
Granted 5,100 options to buy
@ $276.26, valued at
$1.4M
Exercised 317 restricted stock units
@ $0 |
|
| 02/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2021 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 898 shares
@ $288.78, valued at
$259.3k
Exercised 2,007 restricted stock units
@ $0 |
|
| 05/10/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/06/2020 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Sold 1,500 shares
@ $214.1357, valued at
$321.2k
|
|
| 11/04/2020 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 895 shares
@ $207.23, valued at
$185.5k
Exercised 2,006 restricted stock units
@ $0 |
|
| 04/07/2020 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Paid exercise price by delivering 372 shares
@ $113.31, valued at
$42.2k
Exercised 1,010 restricted stock units
@ $0 |
|
| 04/01/2020 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 3,402 shares
@ $0
Paid exercise price by delivering 1,014 shares
@ $131.95, valued at
$133.8k
|
|
| 02/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2020 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 1,680 restricted stock units
@ $0
Granted 7,300 options to buy
@ $182.51, valued at
$1.3M
|
|
| 11/05/2019 |
4
| Kirchgraber Paul R (CEO, Covance Drug Development) has filed a Form 4 on LABORATORY CORP OF AMERICA HOLDINGS|
Txns:
| Granted 6,020 restricted stock units
@ $0 |
|
| 11/01/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |